Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B

Background and Aims Although tenofovir alafenamide (TAF) and besifovir dipivoxil maleate (BSV) are potent antiviral agents in the treatment of chronic hepatitis B (CHB) infection, their renal safety profiles have not been previously compared. This study compared the risk of kidney function decline a...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Liver international 2022-11, Vol.42 (11), p.2408-2417
Hauptverfasser:	Jung, Chan‐Young, Kim, Hyung Woo, Lee, Jung Il, Lee, Hyun Woong, Ahn, Sang Hoon, Kim, Seung Up, Kim, Beom Seok
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral agents antiviral therapy besifovir dipivoxil maleate Chronic infection Glomerular filtration rate Hepatitis Hepatitis B hepatitis B virus Kidney diseases kidney function Kidneys Patients Risk Tenofovir tenofovir alafenamide
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!